Condition: Painful Peripheral Neuropathy · Diabetic Peripheral Neuropathic Pain (DPN) · Chemotherapy Induced Peripheral Neuropathy (CIPN) · Sponsor: University of Rochester
The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks. Participants will: * Undergo a quantitative sensory testing (QST) exam. * Provide a blood sample. * Complete questionnaires on the computer. * Take the study drug as instructed.
This description comes directly from the study's public registry record.
Rachel De Guzman · 585-275-9361 · rachel_deguzman@urmc.rochester.edu
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders | Boston, Massachusetts, United States | Recruiting |
| Ichan School of Medicine at Mount Sinai | New York, New York, United States | Not Yet Recruiting |
| University of Rochester | Rochester, New York, United States | Recruiting |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Not Yet Recruiting |
| University of Vermont | Burlington, Vermont, United States | Recruiting |
| VCU Medical Center | Richmond, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06614322